SEOUL, South Korea – December 2, 2024 – Macrogen Inc. (CEO Changhoon Kim), a global leader in genomic analysis, announced that it held the completion ceremony for its new ‘Macrogen Sejong Campus’ on November 29 at Sejong Technovalley. The event was attended by over 70 key figures and stakeholders, including Sejong City Mayor Min-ho Choi and National Biobank Center Director Hae-young Jung.
The Macrogen Sejong Campus has been designed as a next-generation integrated genome center, equipped with Korea’s top-level genomic analysis and data production capabilities. Built on a 3,570 square meter site within Sejong Technovalley, the campus will function as a ‘Genome Foundry’ to support large-scale genome production d on state-of-the-art automated systems. Following the completion, Macrogen plans to relocate its Daejeon branch's research and service functions to Sejong Campus, establishing it as a hub focused on genome research and production.
Sejong Campus integrates a fully automated system that covers the entire value chain of genome analysis, maximizing efficiency in large-scale genomic research and development. This will enable faster research processes, reduced analysis costs, and the provision of enhanced services to customers.
Furthermore, Macrogen aims to strengthen collaboration with major domestic and international research institutes and companies by expanding cooperation opportunities with Sejong and Osong’s advanced bio/pharmaceutical clusters and bio-campuses, thereby solidifying its market competitiveness.
Mayor Minho Choi commented, "The name of this area, Jiphyeon-dong, means a gathering place for wise people. I hope that promising talents in biotechnology will continue to gather here, and the city will keep investing in the future to foster companies that grow alongside our city."
Macrogen Chairman Jeong-sun Seo stated, "Together with the Macrogen Songdo Global Campus, scheduled for completion in 2026, the Sejong Campus will be a major pillar driving Macrogen’s continuous growth and innovation in the fields of biotechnology and global digital health. This completion marks a new beginning for Macrogen as we aim to transform into an AI and big data-d digital healthcare company by 2030, solidifying our position as a global leader in precision medicine that predicts and prevents diseases."